Literature Archives

Highlights the diagnostic utility and clinical impact of bronchoalveolar lavage in evaluating suspected pneumonia in the ICU.

Artificial intelligence significantly enhances procedural safety and diagnostic accuracy, with robotic bronchoscopy systems achieving biopsy success rates up to 98.8 percent. Clinicians should anticipate these tools driving standardized practices and personalized medicine, despite remaining challenges in algorithm validation and data privacy.

For interventional pulmonologists, the study highlights that while bronchoscopy is overwhelmingly the first-choice biopsy modality at 90.1%, clinicians are heavily reliant on clinical gestalt and face significant administrative and resource burdens, prioritizing better nodule tracking tools and more accurate risk assessment models.

Robotic-assisted bronchoscopy is a viable salvage tool for peripheral tracheobronchial foreign bodies inaccessible to conventional bronchoscopes, as demonstrated by the successful retrieval of a 1.9 cm metallic dental drill from the right lower lobe.

EBUS-TBNA tissue biopsies detected significantly more clinically relevant mutations than blood-based liquid biopsies (39.7% versus 29.6%, yield difference 15.1%, 95% CI 5.5% to 24.2%, P = 0.001). However, since a small percentage of patients had mutations detected in blood only, liquid biopsy remains a complementary tool in clinical practice.

Patients with a high burden of three or more comorbidities achieved comparable functional, physiological, and quality-of-life improvements at 12 months as those with fewer comorbidities, though one-year mortality was 5.4 percent versus zero percent in the lower comorbidity group (P = 0.061). Clinicians should not automatically withhold bronchoscopic lung volume reduction evaluation from severe emphysema patients simply due to multiple comorbid conditions.

Reinforces the role of Whole Lung Lavage (WLL) as the gold standard treatment for symptomatic PAP.

For interventional pulmonologists, the 40 mg dose of inhaled PUR1900 showed a favorable safety profile and was associated with improvements in FEV1 (placebo-adjusted LSM +0.28 L; 95% CI 0.02, 0.53), supporting further phase 3 evaluation.

Mortality involving coexisting lung cancer and sepsis increased over the study period, with the overall age-adjusted mortality rate rising from 1.6 to 2.0 per 100,000 population, highlighting significant demographic and geographic disparities that demand targeted public health strategies and improved access to care.

Multi-day corticosteroid use during chest-tube placement, along with poor performance status, was associated with pleurodesis failure in patients with malignant pleural effusion. Clinicians should interpret these hypothesis-generating findings with caution due to potential confounding factors.

While metered cryospray did not significantly reduce goblet cell density at 6 months (P = 0.49), it improved symptom burden on the St George's Respiratory Questionnaire (-9.6 points, P = 0.022) and reduced radiological air trapping, suggesting it is a safe and promising treatment to explore further in interventional pulmonology practice.

Clinicians should recognize that while bronchial casts are typically removed bronchoscopically, they can occasionally be spontaneously expectorated as cohesive clots, as seen in this rare case of thoracic duct agenesis where the patient declined intervention.